What is Revvity's life sciences — goodwill, acquisition?

Revvity (RVTY) reported life sciences — goodwill, acquisition of $32.04M in Q1 2026.

What does life sciences — goodwill, acquisition mean?

The premium paid over the fair value of net identifiable assets when acquiring businesses within the Life Sciences segment. It represents the value of synergies, brand reputation, and future growth potential expected from the acquisition.

Revvity (RVTY) Life Sciences — Goodwill, Acquisition

Screener

Other segment segments

Diagnostics

$0—

Similar metrics at other companies

DHRLife Sciences — Goodwill

$12.78B-0.8%

ASHLife Sciences — Goodwill

$462M-0.9%

TMOLife Sciences Solutions — Acquisitions

$525.25M-8.7%

BIOLife Science — Goodwill

$490.5M+47.2%

DCILife Sciences Segment — Goodwill

$172.8M+2.2%

DHRLife Sciences — Goodwill Impairment

$0—

Other financials

Income statement

See full

Revenue$711.1M+7.0%

Gross profit$387.7M+3.2%

Operating income$75.9M+5.1%

Net income$40.7M-3.6%

EPS (diluted)$0.36+2.9%

Balance sheet

See full

Cash & equivalents$861.5M-24.3%

Total debt$3.9B+17.8%

Total equity$7.2B-5.9%

Total assets$12.0B-2.9%

Cash flow

See full

Operating cash flow$115.2M-10.1%

CapEx$19.8M+23.7%

Free cash flow$95.5M-14.9%

Valuation

See full

Market cap$12.83B+28.7%

Enterprise value$15.91B+28.6%

P/E53.5×+18.6×

P/S4.4×+0.9×

Profitability

See full

Gross margin48.5%—

Operating margin12.4%-1.1pp

Net margin8.3%-2.1pp

FCF margin17%-1.9pp

Returns & leverage

See full

Return on equity3.2%-0.5pp

Debt / equity0.5×+0.1×

Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept revv:GoodwillAcquisition.

The source filing: Revvity’s 10-Q, filed May 12, 2026.

Filed: May 12, 2026, 4:07 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0000031791-26-000019

Line item	Life Sciences	Diagnostics	Consolidated
Balance at December 28, 2025	$4,744,962	$1,868,531	$6,613,493
Foreign currency translation	(24,952)	(9,826)	(34,778)
Acquisitions	32,035	—	32,035
Balance at April 5, 2026	$4,752,045	$1,858,705	$6,610,750

Item 1.Unaudited Financial Statements

FAQ

What is Revvity's life sciences — goodwill, acquisition?: Revvity (RVTY) reported life sciences — goodwill, acquisition of $32.04M in Q1 2026.
What does life sciences — goodwill, acquisition mean?: The premium paid over the fair value of net identifiable assets when acquiring businesses within the Life Sciences segment. It represents the value of synergies, brand reputation, and future growth potential expected from the acquisition.